12:00 AM
 | 
May 04, 2009
 |  BioCentury  |  Product Development

To the Rescue

Hypoglycemia is the most common side effect of insulin treatment and can result in seizures, unconsciousness and death. Administering glucagon reverses hypoglycemia by facilitating the release of glucose into the bloodstream. Yet, according to Enject Inc., only 900,000 glucagon rescue kits are sold annually in the U.S., where there are 1.4 million Type I diabetics who should have at least one rescue product on hand.

Moreover, the two glucagon rescue products marketed in the U.S. have a total of $70 million in sales. Enject is betting that a safer, more convenient product can grow the market to $200 million or more, and is aiming to bring its GlucaPen glucagon autoinjector to market as early as fall 2010.

Glucagon cannot be premixed, because it breaks down within an hour of reconstitution. Thus the two approved products, one from Eli Lilly and Co. and the other from Novo Nordisk A/S, are kits that require a patient or caregiver...

Read the full 773 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >